China SXT Pharmaceuticals
SXTC
4 hedge funds and large institutions have $139K invested in China SXT Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
111% more capital invested
Capital invested by funds: $66K → $139K (+$72.9K)
100% more funds holding
Funds holding: 2 → 4 (+2)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$57.6K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$38.4K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$19.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$17K |
| 2 |
HF
HRT Financial
New York
|
-$8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $48K | +$57.6K | +3 | New |
|
2
Millennium Management
New York
| $37K | – | – | – |
|
|
TSS
3
Two Sigma Securities
New York
| $24.2K | +$19.2K | +1 | New |
|
|
4
Acadian Asset Management
Boston,
Massachusetts
| $24K | +$38.4K | +2 | New |
|
5
UBS Group
Zurich,
Switzerland
| $5.73K | – | – | – |
|
|
6
Renaissance Technologies
New York
| – | -$17K | -1 | Closed |
|
|
HF
7
HRT Financial
New York
| – | -$8K | – | – |
|
SXTC Hedge Fund Activity: Q4 2022 in Review
4 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q4 2022, worth a combined $139K — up 111% from $66K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SXTC positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $57.6K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $17K sold.
- 4 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q4 2022, up from 2 in Q3 2022.
- Funds reported $139K of China SXT Pharmaceuticals stock for Q4 2022, up 111% quarter-over-quarter.
- 3 funds opened new China SXT Pharmaceuticals positions in Q4 2022 and 1 closed out, a net change of +2 holders.
- The largest China SXT Pharmaceuticals buyer in Q4 2022 was Virtu Financial, an estimated $57.6K added.
- The largest China SXT Pharmaceuticals seller in Q4 2022 was Renaissance Technologies, an estimated $17K sold.
Based on aggregated 13F filings for Q4 2022.